share_log

RBC Capital Upgrades BioCryst Pharma to Outperform, Raises Price Target to $10

Benzinga ·  Sep 18, 2023 07:16

RBC Capital analyst Brian Abrahams upgrades BioCryst Pharma (NASDAQ:BCRX) from Sector Perform to Outperform and raises the price target from $9 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment